Observational studyInternational journal of cancer2026

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry.

Patrick Marschner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.